The transcription factor ZEB1 is aberrantly expressed in aggressive uterine cancers - PubMed (original) (raw)

The transcription factor ZEB1 is aberrantly expressed in aggressive uterine cancers

Nicole S Spoelstra et al. Cancer Res. 2006.

Abstract

The transcription factor ZEB1 (deltaEF1 in mice) has been implicated in cellular processes during development and tumor progression including epithelial to mesenchymal transition. deltaEF1 null mice die at birth, but heterozygotes expressing a LacZ reporter inserted into the deltaEF1 gene live and reproduce. Using these mice, we observed ZEB1 promoter activity in the virgin myometrium, and stroma and myometrium of the pregnant uterus. ZEB1 protein is up-regulated in the myometrium and endometrial stroma after progesterone or estrogen treatment of ovariectomized mice. In the normal human uterus, ZEB1 protein is increased in the myometrium and stroma during the secretory stage of the menstrual cycle. ZEB1 is not expressed in the normal endometrial epithelium. In malignancies of the uterus, we find that ZEB1 (a) is overexpressed in malignant tumors derived from the myometrium (leiomyosarcomas), (b) is overexpressed in tumor-associated stroma of low-grade endometrioid adenocarcinomas, and (c) is aberrantly expressed in the tumor epithelial cells of aggressive endometrial cancers. Specifically, in grade 3 endometrioid adenocarcinomas and uterine papillary serous carcinomas, ZEB1 could be expressed in the epithelial-derived carcinoma cells as well as in the stroma. In malignant mixed Müllerian tumors, the sarcomatous component always expresses ZEB1, and the carcinomatous component can also be positive. In summary, ZEB1 is normally regulated by both estrogen and progesterone receptors, but in uterine cancers, it is likely no longer under control of steroid hormone receptors and becomes aberrantly expressed in epithelial-derived tumor cells, supporting a role for ZEB1 in epithelial to mesenchymal transitions associated with aggressive tumors.

PubMed Disclaimer

Cited by

Constitutive expression of microRNA-150 in mammary epithelium suppresses secretory activation and impairs de novo lipogenesis.
Heinz RE, Rudolph MC, Ramanathan P, Spoelstra NS, Butterfield KT, Webb PG, Babbs BL, Gao H, Chen S, Gordon MA, Anderson SM, Neville MC, Gu H, Richer JK. Heinz RE, et al. Development. 2016 Nov 15;143(22):4236-4248. doi: 10.1242/dev.139642. Epub 2016 Oct 11. Development. 2016. PMID: 27729410 Free PMC article.
ZEB1: at the crossroads of epithelial-mesenchymal transition, metastasis and therapy resistance.
Zhang P, Sun Y, Ma L. Zhang P, et al. Cell Cycle. 2015;14(4):481-7. doi: 10.1080/15384101.2015.1006048. Cell Cycle. 2015. PMID: 25607528 Free PMC article. Review.
MiR-101 suppresses the epithelial-to-mesenchymal transition by targeting ZEB1 and ZEB2 in ovarian carcinoma.
Guo F, Cogdell D, Hu L, Yang D, Sood AK, Xue F, Zhang W. Guo F, et al. Oncol Rep. 2014 May;31(5):2021-8. doi: 10.3892/or.2014.3106. Epub 2014 Mar 21. Oncol Rep. 2014. PMID: 24677166 Free PMC article.
miR-205 acts as a tumour radiosensitizer by targeting ZEB1 and Ubc13.
Zhang P, Wang L, Rodriguez-Aguayo C, Yuan Y, Debeb BG, Chen D, Sun Y, You MJ, Liu Y, Dean DC, Woodward WA, Liang H, Yang X, Lopez-Berestein G, Sood AK, Hu Y, Ang KK, Chen J, Ma L. Zhang P, et al. Nat Commun. 2014 Dec 5;5:5671. doi: 10.1038/ncomms6671. Nat Commun. 2014. PMID: 25476932 Free PMC article.
MicroRNA-23b functions as a tumor suppressor by regulating Zeb1 in bladder cancer.
Majid S, Dar AA, Saini S, Deng G, Chang I, Greene K, Tanaka Y, Dahiya R, Yamamura S. Majid S, et al. PLoS One. 2013 Jul 2;8(7):e67686. doi: 10.1371/journal.pone.0067686. Print 2013. PLoS One. 2013. PMID: 23844063 Free PMC article.

The transcription factor ZEB1 is aberrantly expressed in aggressive uterine cancers - PubMed (original) (raw)